Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery

Journal of Virological Methods

Volumn 196, Issue , 2014, Pages 163-173

  Chahal, Parminder Singh ^a   Schulze, Erica ^a   Tran, Rosa ^a   Montes, Johnny ^a   Kamen, Amine A ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Bioreactor; Gene therapy; Large scale transient transfection; Manufacturing; Process; Production

Indexed keywords

ADENOVIRUS VECTOR; BUTYRIC ACID; PLASMID DNA;

ADENO ASSOCIATED VIRUS; ARTICLE; BIOREACTOR; CONTROLLED STUDY; CULTURE MEDIUM; EMBRYO; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; SCALE UP; SEROTYPE; SUSPENSION CELL CULTURE; VIRAL GENE DELIVERY SYSTEM; VIROGENESIS; VIRUS GENOME; VIRUS INFECTIVITY;

BIOREACTOR; GENE THERAPY; LARGE-SCALE TRANSIENT TRANSFECTION; MANUFACTURING; PROCESS; PRODUCTION;

BIOREACTORS; CULTURE MEDIA, SERUM-FREE; DEPENDOVIRUS; HEK293 CELLS; HUMANS; TRANSFECTION; VIRUS CULTIVATION;

EID: 84889669565     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2013.10.038     Document Type: Article

References (83)

1. Ansorge S., Lanthier S., Transfiguracion J., Durocher Y., Henry O., Kamen A. Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures. J. Gene Med. 2009, 11:868-876.
2. Asokan A., Conway J.C., Phillips J.L., Li C., Hegge J., Sinnott R., Yadav S., DiPrimio N., Nam H.J., Agbandje-McKenna M., McPhee S., Wolff J., Samulski R.J. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat. Biotechnol. 2010, 28:79-82.
3. Asokan A., Schaffer D.V., Samulski R.J. The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 2012, 20:699-708.
4. Aucoin M.G., Perrier M., Kamen A.A. Critical assessment of current adeno-associated viral vector production and quantification methods. Biotechnol. Adv. 2008, 26:73-88.
5. Backliwal G., Hildinger M., Kuettel I., Delegrange F., Hacker D.L., Wurm F.M. Valproic acid: a viable alternative to sodium butyrate for enhancing protein expression in mammalian cell cultures. Biotechnol. Bioeng. 2008, 101:182-189.
6. Bish L.T., Morine K., Sleeper M.M., Sanmiguel J., Wu D., Gao G., Wilson J.M., Sweeney H.L. Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum. Gene Ther. 2008, 19:1359-1368.
7. Boutin S., Monteilhet V., Veron P., Leborgne C., Benveniste O., Montus M.F., Masurier C. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 2010, 21:704-712.
8. Burger C., Gorbatyuk O.S., Velardo M.J., Peden C.S., Williams P., Zolotukhin S., Reier P.J., Mandel R.J., Muzyczka N. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Ther. 2004, 10:302-317.
9. Chadeuf G., Ciron C., Moullier P., Salvetti A. Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery. Mol. Ther. 2005, 12:744-753.
10. Chadeuf G., Favre D., Tessier J., Provost N., Nony P., Kleinschmidt J., Moullier P., Salvetti A. Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome. J. Gene Med. 2000, 2:260-268.
11. Chahal P.S., Aucoin M.G., Kamen A. Primary recovery and chromatographic purification of adeno-associated virus type 2 produced by baculovirus/insect cell system. J. Virol. Methods 2007, 139:61-70.
12. Chang L.S., Shenk T. The adenovirus DNA-binding protein stimulates the rate of transcription directed by adenovirus and adeno-associated virus promoters. J. Virol. 1990, 64:2103-2109.
13. Chang L.S., Shi Y., Shenk T. Adeno-associated virus P5 promoter contains an adenovirus E1A-inducible element and a binding site for the major late transcription factor. J. Virol. 1989, 63:3479-3488.
14. Cheng L., Du C., Murray D., Tong X., Zhang Y.A., Chen B.P., Hawley R.G. A GFP reporter system to assess gene transfer and expression in human hematopoietic progenitor cells. Gene Ther. 1997, 4:1013-1022.
15. Chirmule N., Propert K., Magosin S., Qian Y., Qian R., Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 1999, 6:1574-1583.
16. Clark K.R., Voulgaropoulou F., Fraley D.M., Johnson P.R. Cell lines for the production of recombinant adeno-associated virus. Hum. Gene Ther. 1995, 6:1329-1341.
17. Collaco R.F., Cao X., Trempe J.P. A helper virus-free packaging system for recombinant adeno-associated virus vectors. Gene 1999, 238:397-405.
18. Drittanti L., Jenny C., Poulard K., Samba A., Manceau P., Soria N., Vincent N., Danos O., Vega M. Optimised helper virus-free production of high-quality adeno-associated virus vectors. J. Gene Med. 2001, 3:59-71.
19. Du L., He Y., Wang Y., Zhang H., Ma S., Wong C.K., Wu S.H., Ng F., Huang J.D., Yuen K.Y., Jiang S., Zhou Y., Zheng B.J. Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: implication for developing SARS vaccines. Virology 2006, 353:6-16.
20. Durocher Y., Pham P.L., St-Laurent G., Jacob D., Cass B., Chahal P., Lau C.J., Nalbantoglu J., Kamen A. Scalable serum-free production of recombinant adeno-associated virus type 2 by transfection of 293 suspension cells. J. Virol. Methods 2007, 144:32-40.
21. Eberling J.L., Jagust W.J., Christine C.W., Starr P., Larson P., Bankiewicz K.S., Aminoff M.J. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008, 70:1980-1983.
22. Edelstein M.L., Abedi M.R., Wixon J. Gene therapy clinical trials worldwide to 2007-an update. J. Gene Med. 2007, 9:833-842.
23. Ellis B.L., Potts P.R., Porteus M.H. Creating higher titer lentivirus with caffeine. Hum. Gene Ther. 2011, 22:93-100.
24. Erles K., Sebokova P., Schlehofer J.R. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J. Med. Virol. 1999, 59:406-411.
25. Farson D., Harding T.C., Tao L., Liu J., Powell S., Vimal V., Yendluri S., Koprivnikar K., Ho K., Twitty C., Husak P., Lin A., Snyder R.O., Donahue B.A. Development and characterization of a cell line for large-scale, serum-free production of recombinant adeno-associated viral vectors. J. Gene Med. 2004, 6:1369-1381.
26. Feng L., Guo M., Zhang S., Chu J., Zhuang Y. Optimization of transfection mediated by calcium phosphate for plasmid rAAV-LacZ (recombinant adeno-associated virus-β-galactosidase reporter gene) production in suspension-cultured HEK-293 (human embryonic kidney 293) cells. Biotechnol. Appl. Biochem. 2007, 46:127-135.
27. Gao G.P., Lu F., Sanmiguel J.C., Tran P.T., Abbas Z., Lynd K.S., Marsh J., Spinner N.B., Wilson J.M. Rep/Cap gene amplification and high-yield production of AAV in an A549 cell line expressing Rep/Cap. Mol. Ther. 2002, 5:644-649.
28. Grieger J.C., Choi V.W., Samulski R.J. Production and characterization of adeno-associated viral vectors. Nat. Protoc. 2006, 1:1412-1428.
29. Grieger J.C., Samulski R.J. Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol. 2012, 507:229-254.
30. Hauswirth W.W., Aleman T.S., Kaushal S., Cideciyan A.V., Schwartz S.B., Wang L., Conlon T.J., Boye S.L., Flotte T.R., Byrne B.J., Jacobson S.G. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum. Gene Ther. 2008, 19:979-990.
31. Henry O., Dormond E., Perrier M., Kamen A. Insights into adenoviral vector production kinetics in acoustic filter-based perfusion cultures. Biotechnol. Bioeng. 2004, 86:765-774.
32. Hildinger M., Baldi L., Stettler M., Wurm F.M. High-titer, serum-free production of adeno-associated virus vectors by polyethylenimine-mediated plasmid transfection in mammalian suspension cells. Biotechnol. Lett. 2007, 29:1713-1721.
33. Huang K.S., Lo W.H., Chung Y.C., Lai Y.K., Chen C.Y., Chou S.T., Hu Y.C. Combination of baculovirus-mediated gene delivery and packed-bed reactor for scalable production of adeno-associated virus. Hum. Gene Ther. 2007, 18:1161-1170.
34. Hunt L., Batard P., Jordan M., Wurm F.M. Fluorescent proteins in animal cells for process development: optimization of sodium butyrate treatment as an example. Biotechnol. Bioeng. 2002, 77:528-537.
35. Jiang Z., Sharfstein S.T. Sodium butyrate stimulates monoclonal antibody over-expression in CHO cells by improving gene accessibility. Biotechnol. Bioeng. 2008, 100:189-194.
36. Karolewski B.A., Watson D.J., Parente M.K., Wolfe J.H. Comparison of transfection conditions for a lentivirus vector produced in large volumes. Hum. Gene Ther. 2003, 14:1287-1296.
37. LeWitt P.A., Rezai A.R., Leehey M.A., Ojemann S.G., Flaherty A.W., Eskandar E.N., Kostyk S.K., Thomas K., Sarkar A., Siddiqui M.S., Tatter S.B., Schwalb J.M., Poston K.L., Henderson J.M., Kurlan R.M., Richard I.H., Van Meter L., Sapan C.V., During M.J., Kaplitt M.G., Feigin A. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 2011, 10:309-319.
38. Li J., Samulski R.J., Xiao X. Role for highly regulated rep gene expression in adeno-associated virus vector production. J. Virol. 1997, 71:5236-5243.
39. Lin J., Calcedo R., Vandenberghe L.H., Bell P., Somanathan S., Wilson J.M. A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque. J. Virol. 2009, 83:12738-12750.
40. Liu X., Voulgaropoulou F., Chen R., Johnson P.R., Clark K.R. Selective Rep-Cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines. Mol. Ther. 2000, 2:394-403.
41. Liu Y.L., Wagner K., Robinson N., Sabatino D., Margaritis P., Xiao W., Herzog R.W. Optimized production of high-titer recombinant adeno-associated virus in roller bottles. Biotechniques 2003, 34:184-189.
42. Lock M., Alvira M., Vandenberghe L.H., Samanta A., Toelen J., Debyser Z., Wilson J.M. Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum. Gene Ther. 2010, 21:1259-1271.
43. Logan G.J., Alexander I.E. Adeno-associated virus vectors: immunobiology and potential use for immune modulation. Curr. Gene Ther. 2012, 12:333-343.
44. Maguire A.M., Simonelli F., Pierce E.A., Pugh E.N., Mingozzi F., Bennicelli J., Banfi S., Marshall K.A., Testa F., Surace E.M., Rossi S., Lyubarsky A., Arruda V.R., Konkle B., Stone E., Sun J., Jacobs J., Dell'Osso L., Hertle R., Ma J.X., Redmond T.M., Zhu X., Hauck B., Zelenaia O., Shindler K.S., Maguire M.G., Wright J.F., Volpe N.J., McDonnell J.W., Auricchio A., High K.A., Bennett J. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 2008, 358:2240-2248.
45. Manno C.S., Arruda V.R., Pierce G.F., Glader B., Ragni M., Rasko J., Ozelo M.C., Hoots K., Blatt P., Konkle B., Dake M., Kaye R., Razavi M., Zajko A., Zehnder J., Nakai H., Chew A., Leonard D., Wright J.F., Lessard R.R., Sommer J.M., Tigges M., Sabatino D., Luk A., Jiang H., Mingozzi F., Couto L., Ertl H.C., High K.A., Kay M.A. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 2006, 12:342-347.
46. Manno C.S., Chew A.J., Hutchison S., Larson P.J., Herzog R.W., Arruda V.R., Tai S.J., Ragni M.V., Thompson A., Ozelo M., Couto L.B., Leonard D.G.B., Johnson F.A., McClelland A., Scallan C., Skarsgard E., Flake A.W., Kay M.A., High K.A., Glader B. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003, 101:2963-2972.
47. Mease P.J., Wei N., Fudman E.J., Kivitz A.J., Schechtman J., Trapp R.G., Hobbs K.F., Greenwald M., Hou A., Bookbinder S.A., Graham G.E., Wiesenhutter C.W., Willis L., Ruderman E.M., Forstot J.Z., Maricic M.J., Dao K.H., Pritchard C.H., Fiske D.N., Burch F.X., Prupas H.M., Anklesaria P., Heald A.E. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 study. J. Rheumatol. 2010, 37:692-703.
48. Meghrous J., Aucoin M.G., Jacob D., Chahal P.S., Arcand N., Kamen A.A. Production of recombinant adeno-associated viral vectors using a baculovirus/insect cell suspension culture system: from shake flasks to a 20-L bioreactor. Biotechnol. Progr. 2005, 21:154-160.
49. Mena J.A., Aucoin M.G., Montes J., Chahal P.S., Kamen A.A. Improving adeno-associated vector yield in high density insect cell cultures. J. Gene Med. 2010, 12:157-167.
50. Mingozzi F., Meulenberg J.J., Hui D.J., Basner-Tschakarjan E., Hasbrouck N.C., Edmonson S.A., Hutnick N.A., Betts M.R., Kastelein J.J., Stroes E.S., High K.A. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 2009, 114:2077-2086.
51. Moskalenko M., Chen L., van Roey M., Donahue B.A., Snyder R.O., McArthur J.G., Patel S.D. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J. Virol. 2000, 74:1761-1766.
52. Moss R.B., Milla C., Colombo J., Accurso F., Zeitlin P.L., Clancy J.P., Spencer L.T., Pilewski J., Waltz D.A., Dorkin H.L., Ferkol T., Plan M., Ramsey B., Carter B.J., Martin D.B., Heald A.E. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum. Gene Ther. 2007, 18:726-732.
53. Mueller C., Flotte T.R. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther. 2008, 15:858-863.
54. Myers M.W., Carter B.J. Assembly of adeno-associated virus. Virology 1980, 102:71-82.
55. Nieto K., Weghofer M., Sehr P., Ritter M., Sedlmeier S., Karanam B., Seitz H., Muller M., Kellner M., Horer M., Michaelis U., Roden R.B., Gissmann L., Kleinschmidt J.A. Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS ONE 2012, 7:e39741.
56. Okada T., Mizukami H., Urabe M., Nomoto T., Matsushita T., Hanazono Y., Kume A., Tobita K., Ozawa K. Development and characterization of an antisense-mediated prepackaging cell line for adeno-associated virus vector production. Biochem. Biophys. Res. Commun. 2001, 288:62-68.
57. Palomeque J., Chemaly E.R., Colosi P., Wellman J.A., Zhou S., Del Monte F., Hajjar R.J. Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo. Gene Ther. 2007, 14:989-997.
58. Park J.Y., Lim B.P., Lee K., Kim Y.G., Jo E.C. Scalable production of adeno-associated virus type 2 vectors via suspension transfection. Biotechnol. Bioeng. 2006, 94:416-430.
59. Reed S.E., Staley E.M., Mayginnes J.P., Pintel D.J., Tullis G.E. Transfection of mammalian cells using linear polyethylenimine is a simple and effective means of producing recombinant adeno-associated virus vectors. J. Virol. Methods 2006, 138:85-98.
60. Rutledge E.A., Halbert C.L., Russell D.W. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 1998, 72:309-319.
61. Rybniker J., Nowag A., Janicki H., Demant K., Hartmann P., Buning H. Incorporation of antigens into viral capsids augments immunogenicity of adeno-associated virus vector-based vaccines. J. Virol. 2012, 86:13800-13804.
62. Salvetti A., Oreve S., Chadeuf G., Favre D., Cherel Y., Champion-Arnaud P., David-Ameline J., Moullier P. Factors influencing recombinant adeno-associated virus production. Hum. Gene Ther. 1998, 9:695-706.
63. Sena-Esteves M., Tebbets J.C., Steffens S., Crombleholme T., Flake A.W. Optimized large-scale production of high titer lentivirus vector pseudotypes. J. Virol. Methods 2004, 122:131-139.
64. Sharma A., Ghosh A., Hansen E.T., Newman J.M., Mohan R.R. Transduction efficiency of AAV 2/6, 2/8 and 2/9 vectors for delivering genes in human corneal fibroblasts. Brain Res. Bull. 2010, 81:273-278.
65. Simonelli F., Maguire A.M., Testa F., Pierce E.A., Mingozzi F., Bennicelli J.L., Rossi S., Marshall K., Banfi S., Surace E.M., Sun J., Redmond T.M., Zhu X., Shindler K.S., Ying G.S., Ziviello C., Acerra C., Wright J.F., McDonnell J.W., High K.A., Bennett J., Auricchio A. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol. Ther. 2010, 18:643-650.
66. Sipo I., Knauf M., Fechner H., Poller W., Planz O., Kurth R., Norley S. Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV). Vaccine 2011, 29:1690-1699.
67. Stroes E.S., Nierman M.C., Meulenberg J.J., Franssen R., Twisk J., Henny C.P., Maas M.M., Zwinderman A.H., Ross C., Aronica E., High K.A., Levi M.M., Hayden M.R., Kastelein J.J., Kuivenhoven J.A. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler. Thromb. Vasc. Biol. 2008, 28:2303-2304.
68. Thorne B.A., Takeya R.K., Peluso R.W. Manufacturing recombinant adeno-associated viral vectors from producer cell clones. Hum. Gene Ther. 2009, 20:707-714.
69. Urabe M., Ding C., Kotin R.M. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum. Gene Ther. 2002, 13:1935-1943.
70. Van Vliet K.M., Blouin V., Brument N., Agbandje-McKenna M., Snyder R.O. The role of the adeno-associated virus capsid in gene transfer. Methods Mol. Biol. 2008, 437:51-91.
71. Vidali G., Boffa L.C., Bradbury E.M., Allfrey V.G. Butyrate suppression of histone deacetylation leads to accumulation of multiacetylated forms of histones H3 and H4 and increased DNase I sensitivity of the associated DNA sequences. Proc. Natl. Acad. Sci. U.S.A. 1978, 75:2239-2243.
72. Wagner J.A., Nepomuceno I.B., Messner A.H., Moran M.L., Batson E.P., Dimiceli S., Brown B.W., Desch J.K., Norbash A.M., Conrad C.K., Guggino W.B., Flotte T.R., Wine J.J., Carter B.J., Reynolds T.C., Moss R.B., Gardner P. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum. Gene Ther. 2002, 13:1349-1359.
73. Xiao W., Chirmule N., Berta S.C., McCullough B., Gao G., Wilson J.M. Gene therapy vectors based on adeno-associated virus type 1. J. Virol. 1999, 73:3994-4003.
74. Xiao X. Adeno-associated viral vectors found free in media. Hum. Gene Ther. 2010, 21:1221-1222.
75. Xiao X., Li J., Samulski R.J. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J. Virol. 1996, 70:8098-8108.
76. Xin K.Q., Mizukami H., Urabe M., Toda Y., Shinoda K., Yoshida A., Oomura K., Kojima Y., Ichino M., Klinman D., Ozawa K., Okuda K. Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells. J. Virol. 2006, 80:11899-11910.
77. Xin K.Q., Urabe M., Yang J., Nomiyama K., Mizukami H., Hamajima K., Nomiyama H., Saito T., Imai M., Monahan J., Okuda K., Ozawa K. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum. Gene Ther. 2001, 12:1047-1061.
78. Yang Q., Chen F., Trempe J.P. Characterization of cell lines that inducibly express the adeno-associated virus Rep proteins. J. Virol. 1994, 68:4847-4856.
79. Yla-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol. Ther. 2012, 20:1831-1832.
80. Yuan Y., Liu X.H., Gong D.J., Li B.L., Huang S.D. Recombinant adeno-associated virus mediated RNA interference of angiogenin inhibits growth of human lung squamous cancer cells. Acad. J. Second Mil. Med. Univ. 2007, 28:355-359.
81. Yuan Z., Qiao C., Hu P., Li J., Xiao X. A versatile adeno-associated virus vector producer cell line method for scalable vector production of different serotypes. Hum. Gene Ther. 2011, 22:613-624.
82. Zhou C., Trempe J.P. Induction of apoptosis by cadmium and the adeno-associated virus Rep proteins. Virology 1999, 261:280-287.
83. Zolotukhin S., Byrne B.J., Mason E., Zolotukhin I., Potter M., Chesnut K., Summerford C., Samulski R.J., Muzyczka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999, 6:973-985.